Building an External Innovation Engine

Lessons from the Partnerships That Shape Modern Drug Discovery

Every pharmaceutical company wants innovation.

Very few can generate all of it internally.

The pace of scientific discovery has simply become too fast.

Artificial intelligence.

Cell and gene therapy.

Antibody engineering.

Spatial biology.

Protein degradation.

RNA therapeutics.

Novel delivery systems.

Computational chemistry.

No single organization can realistically become the global leader across every emerging technology while simultaneously advancing hundreds of clinical programs.

That reality has fundamentally changed how pharmaceutical companies compete.

The companies most likely to lead the next decade of innovation will not necessarily invent every breakthrough themselves.

They will build the best external innovation engines.

External Innovation Is Not Business Development

External innovation is often misunderstood as another name for licensing.

It isn't.

Licensing is one outcome.

External innovation is the process that makes successful licensing possible.

The strongest external innovation organizations are constantly scanning the scientific landscape, identifying emerging technologies, evaluating strategic fit, cultivating relationships years before transactions occur, and assembling ecosystems that continuously strengthen the organization's capabilities.

Done well, external innovation becomes a competitive advantage that compounds over time.

Start With Strategy, Not Technology

One of the biggest mistakes organizations make is beginning with the technology.

Instead, they should begin with strategy.

Where are our scientific strengths?

Where are our capability gaps?

Which therapeutic areas are strategically important?

What technologies could accelerate multiple programs rather than a single asset?

What capabilities will we wish we had five years from now?

Only after answering those questions should technology scouting begin.

Otherwise organizations risk collecting interesting science without building a coherent portfolio.

Think in Platforms, Not Products

The most valuable partnerships increasingly revolve around platforms rather than individual assets.

A novel antibody discovery engine.

A computational biology platform.

An AI-enabled target identification system.

A delivery technology.

A manufacturing innovation.

Each has the potential to create value across dozens of future programs.

Platforms generate optionality.

Products consume it.

The strongest external innovation leaders recognize that distinction early.

Relationships Compound Faster Than Transactions

One lesson has remained remarkably consistent throughout my career.

The best partnerships rarely begin with a term sheet.

They begin with curiosity.

A scientific discussion at a conference.

An introduction from a trusted colleague.

An exploratory meeting.

A collaborative research project.

Sometimes those conversations continue for years before a transaction ever occurs.

By the time licensing discussions begin, trust has already been established.

That trust often becomes one of the most valuable assets in the negotiation.

Build an Innovation Ecosystem

No single partnership transforms an organization.

Ecosystems do.

Academic laboratories generate foundational biology.

Biotechnology companies develop novel platforms.

Artificial intelligence companies accelerate discovery.

Contract research organizations expand execution capacity.

Diagnostic companies improve patient selection.

Large pharmaceutical organizations contribute development expertise, regulatory capabilities, manufacturing, and global commercialization.

Every participant strengthens the network.

Every successful partnership increases the value of future partnerships.

That is how innovation ecosystems become self-reinforcing.

Artificial Intelligence Changes the Equation

Artificial intelligence is not simply another technology category.

It is becoming an enabling layer across every stage of drug discovery and development.

Target identification.

Protein engineering.

Clinical trial design.

Biomarker discovery.

Companion diagnostics.

Manufacturing.

Medical writing.

Regulatory submissions.

Commercial forecasting.

This creates a new challenge for external innovation teams.

The question is no longer simply whether an AI company has an impressive algorithm.

The question is whether its platform integrates naturally into scientific workflows, produces reproducible results, and earns the confidence of researchers, regulators, and enterprise leadership.

Trust has become a strategic differentiator.

Partner for Learning, Not Just Products

The strongest partnerships create more than revenue.

They create learning.

Every collaboration generates data.

Every experiment produces new biological insight.

Every clinical program improves future decision making.

Organizations that consistently learn faster than competitors create sustainable advantages that extend well beyond individual products.

External innovation should therefore be measured not only by the number of deals completed, but by how much organizational capability each partnership creates.

Commercialization Begins on Day One

One of the most overlooked aspects of external innovation is commercialization.

Many organizations assume commercialization begins after proof of concept.

It actually begins during partner evaluation.

Can the technology scale?

Will scientists adopt it?

Can manufacturing support it?

Will payers recognize its value?

Can regulatory pathways be clearly defined?

Does the partnership strengthen the broader portfolio?

Commercial success is rarely determined by one spectacular experiment.

It is determined by hundreds of strategic decisions made long before the first patient is treated.

Looking Ahead

The pharmaceutical companies that define the next decade will not simply execute better licensing deals.

They will build organizations that continuously identify, evaluate, integrate, and commercialize external innovation more effectively than anyone else.

That requires scientific curiosity.

Commercial discipline.

Strategic patience.

Cross-functional leadership.

And perhaps most importantly, the ability to recognize not only today's breakthrough, but tomorrow's platform.

Because the ultimate objective of external innovation is not acquiring technologies.

It is building an organization that continuously becomes better at discovering, developing, and delivering the medicines patients will need next.